11 – 20 of 77
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
-
Mark
S100A9 expressed in ER(-)PgR(-) breast cancers induces inflammatory cytokines and is associated with an impaired overall survival.
(
- Contribution to journal › Article
-
Mark
Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
(
- Contribution to journal › Article
- 2014
-
Mark
Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment.
(
- Contribution to journal › Article
-
Mark
The quinoline-3-carboxamide paquinimod (ABR-215757) reduces leukocyte recruitment during sterile inflammation: Leukocyte- and context-specific effects.
(
- Contribution to journal › Article
-
Mark
High density of S100A9 positive inflammatory cells in prostate cancer stroma is associated with poor outcome.
(
- Contribution to journal › Article
-
Mark
Quinoline-3-carboxamides modulate primary T cell-dependent B cell responses but do not inhibit functional immunity.
(
- Contribution to journal › Article
- 2013
-
Mark
Increased serum levels of S100A8/A9 and S100A12 are associated with cardiovascular disease in patients with inactive systemic lupus erythematosus.
(
- Contribution to journal › Article
-
Mark
Amelioration of Experimental Autoimmune Encephalomyelitis by the Quinoline-3-Carboxamide Paquinimod (ABR-215757): Reduced Priming of Proinflammatory Effector CD4(+) T Cells.
(
- Contribution to journal › Article
-
Mark
The radical-binding lipocalin A1M binds to a Complex I subunit and protects mitochondrial structure and function.
(
- Contribution to journal › Article
-
Mark
Common Interactions between S100A4 and S100A9 Defined by a Novel Chemical Probe.
(
- Contribution to journal › Article